OKYO Pharma Ltd OKYO

Healthcare SIC 2836 - Biological Products, (No Diagnostic Substances) NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Biological Product (except Diagnostic) Manufacturing derived Nasdaq

Last close —

Market cap —

52-week range — - —

No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.

Valuation FY2026 figures against the last close

P/S—

P/E—

P/FCF—

EV/EBITDA—

Dividend yield—

Diluted EPS—

Annual financial statements

Income statement

Fiscal year	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Net income	—	—	-$4.7M	-$16.8M	-$13.3M	-$5.4M	-$3.4M	-$1.5M	—

Balance sheet

Fiscal year	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Total assets	—	—	$3.7M	$1.5M	$5.2M	$4.3M	$7.1M	—	—
Total equity	—	—	-$5.5M	-$5.9M	-$2.1M	$2.9M	$5.3M	-$140.1K	$333.2K

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-036599.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)

Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity

Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks

No annual figures to plot for this company yet.

Others in SIC 2836

Ticker	Company	Market cap	P/E	Revenue growth
AMGN	AMGEN INC	$236.38B	30.7x	10.0%
GILD	GILEAD SCIENCES, INC.	$187.23B	22.3x	2.4%
MRNA	Moderna, Inc.	$58.11B	—	-39.9%
RVMD	Revolution Medicines, Inc.	$45.01B	—	—
BIIB	BIOGEN INC.	$32.60B	25.1x	2.2%
SCNI	Scinai Immunotherapeutics Ltd.	$25.80B	—	99.2%
NBIX	NEUROCRINE BIOSCIENCES INC	$15.82B	33.3x	21.4%
EXEL	EXELIXIS, INC.	$14.62B	21.2x	7.0%